blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2720707

EP2720707 - ANTI-INFLAMMATORY PHARMACEUTICAL PRODUCTS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  25.10.2019
Database last updated on 16.09.2024
FormerThe patent has been granted
Status updated on  16.11.2018
FormerGrant of patent is intended
Status updated on  13.03.2018
FormerExamination is in progress
Status updated on  03.01.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
ResoTher Pharma ApS
"Næsseslottet"
Dronninggårds Alle 136
2840 Holte / DK
[2017/11]
Former [2016/41]For all designated states
Enteris BioPharma, Inc.
83 Fulton Street
Boonton, NJ 07005 / US
Former [2014/17]For all designated states
UGP Therapeutics, Inc.
227 W. Monroe Street, Suite 3900
Chicago, IL 60606 / US
Inventor(s)01 / CONSALVO, Angelo, P.
105 Fredrick Drive
Monroe, NY 10950 / US
02 / MEHTA, Nozer, M.
14 Old Coach Road
Randolph, NJ 07869 / US
03 / PERRETTI, Mauro
203 Goldhurst Terrace
London NW6 3ER / GB
04 / DALLI, Jesmond
369 Tappan Street Apt. 10
Brookline, MA 02445 / US
 [2014/17]
Representative(s)Høiberg P/S
Adelgade 12
1304 Copenhagen K / DK
[2018/51]
Former [2014/17]Sutcliffe, Nicholas Robert, et al
Mewburn Ellis LLP
33 Gutter Lane
London
EC2V 8AS / GB
Application number, filing date12799815.115.06.2012
[2018/51]
WO2012US42699
Priority number, dateUS201161497270P15.06.2011         Original published format: US 201161497270 P
US20121352438115.06.2012         Original published format: US201213524381
[2014/17]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2012174397
Date:20.12.2012
Language:EN
[2012/51]
Type: A2 Application without search report 
No.:EP2720707
Date:23.04.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 20.12.2012 takes the place of the publication of the European patent application.
[2014/17]
Type: B1 Patent specification 
No.:EP2720707
Date:19.12.2018
Language:EN
[2018/51]
Search report(s)International search report - published on:US28.02.2013
(Supplementary) European search report - dispatched on:EP10.04.2015
ClassificationIPC:A61K38/17
[2014/17]
CPC:
A61K38/1709 (EP,US); C07K14/4721 (EP,CN,US); C07K14/4703 (US);
A61P29/00 (EP); A61K38/00 (EP,CN,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/17]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ENTZÜNDUNGSHEMMENDE PHARMAZEUTISCHE PRODUKTE[2014/17]
English:ANTI-INFLAMMATORY PHARMACEUTICAL PRODUCTS[2014/17]
French:PRODUITS PHARMACEUTIQUES ANTI-INFLAMMATOIRES[2014/17]
Entry into regional phase19.12.2013National basic fee paid 
19.12.2013Search fee paid 
19.12.2013Designation fee(s) paid 
19.12.2013Examination fee paid 
Examination procedure19.12.2013Examination requested  [2014/17]
30.10.2015Amendment by applicant (claims and/or description)
10.03.2016Despatch of a communication from the examining division (Time limit: M06)
28.12.2016Reply to a communication from the examining division
31.03.2017Despatch of a communication from the examining division (Time limit: M06)
09.10.2017Reply to a communication from the examining division
14.03.2018Communication of intention to grant the patent
30.08.2018Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
05.11.2018Fee for grant paid
05.11.2018Fee for publishing/printing paid
05.11.2018Receipt of the translation of the claim(s)
Divisional application(s)EP18212844.7  / EP3533457
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  10.03.2016
Opposition(s)20.09.2019No opposition filed within time limit [2019/48]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
05.11.2018Request for further processing filed
05.11.2018Full payment received (date of receipt of payment)
Request granted
20.11.2018Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
28.12.2016Request for further processing filed
28.12.2016Full payment received (date of receipt of payment)
Request granted
19.01.2017Decision despatched
Fees paidRenewal fee
31.03.2014Renewal fee patent year 03
10.06.2015Renewal fee patent year 04
10.06.2016Renewal fee patent year 05
01.06.2017Renewal fee patent year 06
08.06.2018Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL19.12.2018
CY19.12.2018
CZ19.12.2018
EE19.12.2018
FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
MC19.12.2018
MK19.12.2018
MT19.12.2018
RO19.12.2018
RS19.12.2018
SI19.12.2018
SK19.12.2018
SM19.12.2018
BG19.03.2019
GR20.03.2019
IS19.04.2019
PT19.04.2019
LU15.06.2019
[2022/31]
Former [2021/34]AL19.12.2018
CY19.12.2018
CZ19.12.2018
EE19.12.2018
FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
MC19.12.2018
MT19.12.2018
RO19.12.2018
RS19.12.2018
SI19.12.2018
SK19.12.2018
SM19.12.2018
BG19.03.2019
GR20.03.2019
IS19.04.2019
PT19.04.2019
LU15.06.2019
Former [2021/26]AL19.12.2018
CY19.12.2018
CZ19.12.2018
EE19.12.2018
FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
MC19.12.2018
RO19.12.2018
RS19.12.2018
SI19.12.2018
SK19.12.2018
SM19.12.2018
BG19.03.2019
GR20.03.2019
IS19.04.2019
PT19.04.2019
LU15.06.2019
Former [2020/27]AL19.12.2018
CZ19.12.2018
EE19.12.2018
FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
MC19.12.2018
RO19.12.2018
RS19.12.2018
SI19.12.2018
SK19.12.2018
SM19.12.2018
BG19.03.2019
GR20.03.2019
IS19.04.2019
PT19.04.2019
LU15.06.2019
Former [2020/13]AL19.12.2018
CZ19.12.2018
EE19.12.2018
FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
MC19.12.2018
RO19.12.2018
RS19.12.2018
SI19.12.2018
SK19.12.2018
SM19.12.2018
BG19.03.2019
GR20.03.2019
IS19.04.2019
PT19.04.2019
Former [2020/08]AL19.12.2018
CZ19.12.2018
EE19.12.2018
FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
MC19.12.2018
RO19.12.2018
RS19.12.2018
SK19.12.2018
SM19.12.2018
BG19.03.2019
GR20.03.2019
IS19.04.2019
PT19.04.2019
Former [2019/39]AL19.12.2018
CZ19.12.2018
EE19.12.2018
FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
RO19.12.2018
RS19.12.2018
SK19.12.2018
SM19.12.2018
BG19.03.2019
GR20.03.2019
IS19.04.2019
PT19.04.2019
Former [2019/37]AL19.12.2018
CZ19.12.2018
EE19.12.2018
FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
RO19.12.2018
RS19.12.2018
SM19.12.2018
BG19.03.2019
GR20.03.2019
PT19.04.2019
Former [2019/35]AL19.12.2018
CZ19.12.2018
FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
RS19.12.2018
BG19.03.2019
GR20.03.2019
PT19.04.2019
Former [2019/33]AL19.12.2018
FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
RS19.12.2018
BG19.03.2019
GR20.03.2019
PT19.04.2019
Former [2019/26]AL19.12.2018
FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
RS19.12.2018
BG19.03.2019
GR20.03.2019
Former [2019/25]FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
RS19.12.2018
BG19.03.2019
GR20.03.2019
Former [2019/23]FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
BG19.03.2019
Former [2019/22]FI19.12.2018
LT19.12.2018
BG19.03.2019
Former [2019/21]FI19.12.2018
LT19.12.2018
Former [2019/20]LT19.12.2018
Documents cited:Search[XI]WO2006039621  (UNIV NEW JERSEY MED [US], et al) [X] 1 * figure 2B *[I] 2-4,12-15
International search[Y]WO2008121881  (UNIV NEW YORK STATE RES FOUND [US], et al);
 [Y]US2009163578  (DOROVKOV MAXIM V [US], et al);
 [Y]WO2010043045  (LONDON HEALTH SCI CT RES INC [CA], et al);
 [Y]  - HU ET AL., "Membrane-Induced Folding and Structure of Membrane-Bound Annexin A1 N-Terminal peptides: Implications for Annexin-Induced Membrane Aggregation", BIOPHYS. J., (200803), vol. 94, pages 1773 - 1781, XP055135709

DOI:   http://dx.doi.org/10.1529/biophysj.107.119685
 [A]  - ZHANG ET AL., "Annexin 1 induced by anti-inflammatory drugs binds to NF-kappaB and inhibits its activation: anticancer effects in vitro and in vivo", CANCER RES., (20100315), vol. 70, no. 6, pages 2379 - 2388, XP055135710

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-09-4204
by applicantUS4708934
 EP0308067
 EP0382403
 US6086018
 US6103495
 US2006292672
 US7445911
 US2009317462
    - Biotechnology, (19930000), vol. 11, pages 64 - 70
    - RAY et al., Protein Expression and Purification, (20020000), vol. 26, pages 249 - 259
    - MEHTA, Biopharm. International, (20040700), pages 44 - 46
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.